Search Within

Gastrointestinal Oncology Service

Formats
  1. Journal Article (2349)
  2. Meeting Abstract (1870)
  3. Review (150)
  4. Book Section (127)
  5. Editorial (100)
  6. Guidelines (39)
  7. Correspondence (34)
  8. Conference Paper (24)
  9. Miscellaneous (22)
  10. Research Letter (17)
  11. Book Whole (12)
Groups
  1. Solid Tumor Oncology Division (4744)
  2. Department of Medicine (4742)
  3. Center for Pancreatic Cancer Research (2312)
  4. Surgery (1065)
  5. Survivorship Research (1013)
  6. Epidemiology and Biostatistics (842)

More Groups

People
  1. Eileen O'Reilly (803)
  2. Leonard Saltz (796)
  3. Ghassan Abou-Alfa (583)
  4. Nancy Kemeny (545)
  5. David Kelsen (538)
  6. David Ilson (443)

More People

Years
  1. 2025 (219)
  2. 2024 (309)
  3. 2023 (362)
  4. 2022 (346)
  5. 2021 (345)
  6. 2020 (326)

More Years

Publications
  1. Journal of Clinical Oncology (1290)
  2. Annals of Oncology (331)
  3. Annals of Surgical Oncology (147)
  4. Cancer (128)
  5. Clinical Cancer Research (107)
  6. Cancer Research (94)

More Publications

Publishers
  1. American Society of Clinical Oncology (1379)
  2. Oxford University Press (462)
  3. Elsevier Inc. (408)
  4. Springer (320)
  5. American Association for Cancer Research (281)
  6. Wiley Blackwell (241)

More Publishers

Results (4744)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A novel microbiome signature in gastric cancer: A two independent cohort retrospective analysis
    Conference Paper

    Abate, M.; Vos, E.; Gonen, M.; Janjigian, Y. Y.; Schattner, M.; Laszkowska, M.; Tang, L.; Maron, S. B.; Coit, D. G.; Vardhana, S.; more...
    Lippincott Williams & Wilkins (2022)

    Fulltext@MSK | Save
  • Primary analysis of MOUNTAINEER: A phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC
    Meeting Abstract

    Strickler, J.; Cercek, A.; Siena, S.; André, T.; Ng, K.; Van Cutsem, E.; Wu, C.; Paulson, A.; Hubbard, J.; Coveler, A.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase 3 HIMALAYA study
    Meeting Abstract

    Vogel, A.; Chan, S.; Furuse, J.; Tak, W.; Masi, G.; Varela, M.; Kim, J.; Tanasanvimon, S.; Reig, M.; Dayyani, F.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Evaluating age as a factor for survival and quality of life in patients with BRAF V600E-mutant metastatic colorectal cancer treated with encorafenib + cetuximab ± binimetinib: Subanalysis of BEACON CRC
    Meeting Abstract

    Ng, K.; Ciardiello, F.; Van Cutsem, E.; Yaeger, R.; Yoshino, T.; Desai, J.; Wasan, H.; Alkuzweny, B.; Zhang, X.; Tabernero, J.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Feasibility, safety, and biodistribution of 18F-BMS-986229 PET in patients with esophagogastric (EG) cancer
    Meeting Abstract

    Cytryn, S.; Lumish, M.; Paroder, V.; Philemond, S.; Lewis, J.; Lyashchenko, S.; Janjigian, Y.; Pandit-Taskar, N.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Novel frailty index predicts short-term outcomes after esophagectomy in elderly patients with esophageal cancer
    Meeting Abstract

    Boerner, T.; Tin, A.; Vickers, A.; Harrington, C.; Janjigian, Y.; Ilson, D.; Wu, A.; Bott, M.; Isbell, J.; Park, B.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Co-occurring HER2 and PD-L1 expression in patients with HER2-positive trastuzumab-refractory gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): Biomarker analysis from the trastuzumab deruxtecan (T-DXd) DESTINY-Gastric03 trial
    Meeting Abstract

    Janjigian, Y.; Rha, S.; Oh, D.; Díez García, M.; van Laarhoven, H.; Chao, Y.; Di Bartolomeo, M.; Haj Mohammad, N.; Zhong, W.; Croydon, E.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Phase II study (daNIS-3) of the antieTGF-β monoclonal antibody NIS793 and other new investigational drug combinations with standard-of-care therapy vs standard-of-care alone in patients with second-line metastatic colorectal cancer
    Meeting Abstract

    Segal, N.; Rivera, F.; Tournigand, C.; Kasper, S.; Chen, Y.; Deshpande, P.; Messmann, R.; Kopetz, S.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • A phase 2, multi-center, open-label study of cinrebafusp alfa (PRS-343) in patients with HER2-high and HER2-low gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Meeting Abstract

    Ku, G.; Piha-Paul, S.; Gupta, M.; Oh, D.; Kim, Y.; Lee, J.; Rha, S.; Kang, Y.; Diez García, M.; Fleitas Kanonnikoff, T.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Evaluating sex as a predictive marker for response to bevacizuamb in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database
    Meeting Abstract

    Margalit, O.; Harmsen, W.; Shacham-Shmueli, E.; Voss, M.; Boursi, B.; Cohen, R.; Olswold, C.; Saltz, L.; Hurwitz, H.; Adams, R.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save